🔗 Visit the ClinicalTrials.gov page for NCT02396108
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. | N Engl J Med | 2005 | 33.60 |
| 2 | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | J Clin Oncol | 2011 | 4.81 |
| 3 | Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. | Target Oncol | 2022 | 0.75 |